iBio, Inc.

GRI Bio, Inc.

Supernus Pharmaceuticals, Inc.

Eikon Therapeutics, Inc.

Candel Therapeutics, Inc.

Compass Therapeutics, Inc.

Lexicon Pharmaceuticals, Inc.

Cartesian Therapeutics, Inc.

Annovis Bio, Inc.

Dilution score: 65/100 (HIGH), 19.9 months cash

13F fund flow: neutral, ? institutional managers

PHI-501, a dual inhibitor of RAF and DDR1/2, overcomes MAPK drug resistance in Melanoma.

Efficacy and safety of momelotinib in Janus kinase inhibitor-experienced Asian patients with myelofibrosis and anemia.

Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study.

Adjuvant Systemic Therapies for Resected Stages III and IV Melanoma: A Multi-Center Retrospective Clinical Study.

Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study.

Short interest: 11.94% of float, squeeze risk: MODERATE

SW convergence: 50/100 (Neutral), 1 bullish / 0 bearish signals

<article class="bts-verified-summary" data-ticker="IBIO">
<p>iBio, Inc. (IBIO) is the lead sponsor of 1 active clinical trials listed on ClinicalTrials.gov<sup><a href="#fn-2">[2]</a></sup>, including 1 Phase 1<sup><a href="#fn-1">[1]</a></sup>.</p>
<p>IBIO has 1 Form 4 insider filing recorded at the SEC in the past 30 days<sup><a href="#fn-3">[3]</a></sup>.</p>
<section class="sources" data-nosnippet aria-label="Sources"><h3>Sources</h3><ol><li id="fn-1">ClinicalTrials.gov (2026-06-17) <a href="https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22iBio%2C+Inc.%22&amp;aggFilters=status%3Arec%2Cact" rel="nofollow noopener noreferrer">↗</a></li>
<li id="fn-2">ClinicalTrials.gov (2026-06-17) <a href="https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22iBio%2C+Inc.%22&amp;aggFilters=status%3Arec%2Cact" rel="nofollow noopener noreferrer">↗</a></li>
<li id="fn-3">SEC EDGAR · 0001420720 (2026-06-17) <a href="https://efts.sec.gov/LATEST/search-index?q=%22IBIO%22&amp;forms=4&amp;dateRange=custom&amp;startdt=2026-05-18&amp;enddt=2026-06-17" rel="nofollow noopener noreferrer">↗</a></li></ol></section>
</article>

ClinicalTrials.gov

SEC EDGAR — 0001420720

iBio, Inc. (IBIO) — BioTechSigns Verified Summary

iBio, Inc. (IBIO) is the lead sponsor of 1 active clinical trials listed on ClinicalTrials.gov[2], including 1 Phase 1[1].

IBIO has 1 Form 4 insider filing recorded at the SEC in the past 30 days[3].

Sources:
[1] ClinicalTrials.gov. Source last updated 2026-06-17, retrieved 2026-06-17.
    https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22iBio%2C+Inc.%22&aggFilters=status%3Arec%2Cact
[2] ClinicalTrials.gov. Source last updated 2026-06-17, retrieved 2026-06-17.
    https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22iBio%2C+Inc.%22&aggFilters=status%3Arec%2Cact
[3] SEC EDGAR, 0001420720. Source last updated 2026-06-17, retrieved 2026-06-17.
    https://efts.sec.gov/LATEST/search-index?q=%22IBIO%22&forms=4&dateRange=custom&startdt=2026-05-18&enddt=2026-06-17

The goal of this clinical trial is to learn which dose of study drug IBIO-600 has the right balance of safety, tolerability and impact on body composition in overweight and obese adult participants.